Aconoidasida

Aconoidasida is a subclass of Apicomplexa, a large phylum of parasitic protists. They are characterized by the presence of an apical complex, a group of organelles and structures that are involved in host cell invasion. The subclass Aconoidasida includes important human pathogens such as the malaria parasite Plasmodium and the babesiosis parasite Babesia.

Characteristics

Members of the subclass Aconoidasida are distinguished by the absence of a conoid, a cone-shaped structure at the apical end of the cell, during certain stages of their life cycle. This is in contrast to the related subclass Conoidasida, which possess a conoid at all stages of their life cycle.

Taxonomy

The subclass Aconoidasida is divided into two orders: Haemospororida and Piroplasmorida. The order Haemospororida includes the genera Plasmodium, Haemoproteus, and Leucocytozoon, which are parasites of vertebrates and are transmitted by insects. The order Piroplasmorida includes the genera Babesia and Theileria, which are parasites of vertebrates and are transmitted by ticks.

Pathogenesis

Several species of Aconoidasida are significant pathogens of humans and other animals. Plasmodium species cause malaria, a disease that affects millions of people worldwide each year. Babesia species cause babesiosis, a less common but still serious disease that can be fatal in people with weakened immune systems.

Treatment and Control

Treatment of diseases caused by Aconoidasida parasites typically involves antiparasitic drugs. For malaria, drugs such as chloroquine, artemisinin, and mefloquine are commonly used. For babesiosis, a combination of atovaquone and azithromycin is often effective.

Control of Aconoidasida diseases primarily involves controlling the insect or tick vectors that transmit the parasites. This can include the use of insecticides, bed nets, and other measures to reduce contact between humans and vectors.

Aconoidasida Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.